Hyperproinsulinemia in obesity and in type 2 diabetes and its relation to cardiovascular disease

References

• Steiner DF, Cunningham D, Spigelman L, et al. Insulin biosynthesis: evidence for a precursor. Science. 1967;157(3789):697–700.
   PubMed Web of Science ®Google Scholar
• Haataja L, Manickam N, Soliman A, et al. Disulfide mispairing during proinsulin folding in the endoplasmic reticulum. Diabetes. 2016;65(4):1050–1060.
   PubMed Web of Science ®Google Scholar
• Weiss M, Steiner DF, Philipson LH. Insulin biosynthesis, secretion, structure, and structure-activity relationships [internet]. In: Endotext. De Groot LJ, Beck-Peccoz P, Chrousos G et al. Eds. MDText.com, Inc: South Dartmouth (MA). 2000. cited 2016 Jul 5. Available from: http://www.ncbi.nlm.nih.gov/books/NBK279029/
   Google Scholar
• Halban PA. Structural domains and molecular lifestyles of insulin and its precursors in the pancreatic beta cell. Diabetologia. 1991;34(11):767–778.
   PubMed Web of Science ®Google Scholar
• Steiner DF. The proinsulin C-peptide – a multirole model. Exp Diabesity Res. 2004;5(1):7–14.
   PubMedGoogle Scholar
• Tillil H, Frank BH, Pekar AH, et al. Hypoglycemic potency and metabolic clearance rate of intravenously administered human proinsulin and metabolites. Endocrinology. 1990;127(5):2418–2422.
   PubMed Web of Science ®Google Scholar
• Andersen L, Dinesen B, Jørgensen PN, et al. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem. 1993;39(4):578–582.
   PubMed Web of Science ®Google Scholar
• Kjems LL, Røder ME, Dinesen B, et al. Highly sensitive enzyme immunoassay of proinsulin immunoreactivity with use of two monoclonal antibodies. Clin Chem. 1993;39(10):2146–2150.
   PubMed Web of Science ®Google Scholar
• Houssa P, Dinesen B, Deberg M, et al. First direct assay for intact human proinsulin. Clin Chem. 1998;44(7):1514–1519.
   PubMed Web of Science ®Google Scholar
• Karaderi T, Drong AW, Lindgren CM. Insights into the genetic susceptibility to type 2 diabetes from genome-wide association studies of obesity-related traits. Curr Diab Rep. 2015;15(10):83.
   PubMed Web of Science ®Google Scholar
• Ward WK, LaCava EC, Paquette TL, et al. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia. 1987;30(9):698–702.
   PubMed Web of Science ®Google Scholar
• Temple RC, Carrington CA, Luzio SD, et al. Insulin deficiency in non-insulin-dependent diabetes. Lancet. 1989;1(8633):293–295.
   PubMed Web of Science ®Google Scholar
• Røder ME, Vaag A, Hartling SG, et al. Proinsulin immunoreactivity in identical twins discordant for noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1995;80(8):2359–2363.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Halban PA. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes. 1997;46(11):1725–1732.
   PubMed Web of Science ®Google Scholar
• Røder ME, Dinesen B, Poulsen F. Measurement of insulin immunoreactivity in human plasma and serum. Clin Chem. 2009;55(7):1425–1426.
   PubMed Web of Science ®Google Scholar
• Ward WK, Paquette TL, Frank BH, et al. A sensitive radioimmunoassay for human proinsulin, with sequential use of antisera to C-peptide and insulin. Clin Chem. 1986;32(5):728–733.
   PubMed Web of Science ®Google Scholar
• Sobey WJ, Beer SF, Carrington CA, et al. Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. Biochem J. 1989;260(2):535–541.
   PubMed Web of Science ®Google Scholar
• Pfützner A, Pfützner AH, Kann PH, et al. Clinical and laboratory evaluation of a new specific ELISA for intact proinsulin. Clin Lab. 2005;51(5–6):243–249.
   PubMed Web of Science ®Google Scholar
• Given BD, Cohen RM, Shoelson SE, et al. Biochemical and clinical implications of proinsulin conversion intermediates. J Clin Invest. 1985;76(4):1398–1405.
   PubMed Web of Science ®Google Scholar
• Linde S, Røder ME, Hartling SG, et al. Separation and quantitation of serum proinsulin and proinsulin intermediates in humans. J Chromatogr. 1991;548(1–2):371–380.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853.
   PubMed Web of Science ®Google Scholar
• Pfützner A, Pfützner AH, Kann PH, et al. Clinical and laboratory evaluation of a new specific point-of-care test for intact proinsulin. J Diabetes Sci Technol. 2017;11(2):278–283.
   PubMedGoogle Scholar
• Røder ME, Dinesen B, Hartling SG, et al. Intact proinsulin and beta-cell function in lean and obese subjects with and without type 2 diabetes. Diabetes Care. 1999;22(4):609–614.
   PubMed Web of Science ®Google Scholar
• Ozawa S, Katsuta H, Suzuki K, et al. Estimated proinsulin processing activity of prohormone convertase (PC) 1/3 rather than PC2 is decreased in pancreatic β-cells of type 2 diabetic patients. Endocr J. 2014;61(6):607–614.
   PubMed Web of Science ®Google Scholar
• Reaven GM, Chen YD, Hollenbeck CB, et al. Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. J Clin Endocrinol Metab. 1993;76(1):44–48.
   PubMed Web of Science ®Google Scholar
• Sizonenko SV, Halban PA. Differential rates of conversion of rat proinsulins I and II. Evidence for slow cleavage at the B-chain/C-peptide junction of proinsulin II. Biochem J. 1991;278(Pt 3):621–625.
   PubMed Web of Science ®Google Scholar
• Hartling SG, Røder ME, Dinesen B, et al. Proinsulin C-peptide, and insulin in normal subjects during an 8-h hyperglycemic clamp. Eur J Endocrinol. 1996;134(2):197–200.
   PubMed Web of Science ®Google Scholar
• Loopstra-Masters RC, Haffner SM, Lorenzo C, et al. Proinsulin-to-C-peptide ratio versus proinsulin-to-insulin ratio in the prediction of incident diabetes: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetologia. 2011;54(12):3047–3054.
   PubMed Web of Science ®Google Scholar
• Røder ME, Eriksson J, Hartling SG, et al. Proportional proinsulin responses in first-degree relatives of patients with type 2 diabetes mellitus. Acta Diabetol. 1993;30(3):132–137.
   PubMed Web of Science ®Google Scholar
• Mykkänen L, Zaccaro DJ, Hales CN, et al. The relation of proinsulin and insulin to insulin sensitivity and acute insulin response in subjects with newly diagnosed type II diabetes: the Insulin Resistance Atherosclerosis Sstudy. Diabetologia. 1999;42(9):1060–1066.
   PubMed Web of Science ®Google Scholar
• Røder ME, Schwartz RS, Prigeon RL, et al. Reduced pancreatic B cell compensation to the insulin resistance of aging: impact on proinsulin and insulin levels. J Clin Endocrinol Metab. 2000;85(6):2275–2280.
   PubMed Web of Science ®Google Scholar
• Zethelius B, Byberg L, Hales CN, et al. Proinsulin and acute insulin response independently predict type 2 diabetes mellitus in men – report from 27 years of follow-up study. Diabetologia. 2003;46(1):20–26.
   PubMed Web of Science ®Google Scholar
• Yoshioka N, Kuzuya T, Matsuda A, et al. Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1988;31(6):355–360.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Siegel EG, Creutzfeldt W. Prolonged maximal stimulation of insulin secretion in healthy subjects does not provoke preferential release of proinsulin. Pancreas. 1991;6(6):645–652.
   PubMed Web of Science ®Google Scholar
• Leahy JL, Weir GC. Evolution of abnormal insulin secretory responses during 48-h in vivo hyperglycemia. Diabetes. 1988;37(2):217–222.
   PubMed Web of Science ®Google Scholar
• Björklund A, Grill V. Enhancing effects of long-term elevated glucose and palmitate on stored and secreted proinsulin-to-insulin ratios in human pancreatic islets. Diabetes. 1999;48(7):1409–1414.
   PubMed Web of Science ®Google Scholar
• Hostens K, Ling Z, Van Schravendijk C, et al. Prolonged exposure of human beta-cells to high glucose increases their release of proinsulin during acute stimulation with glucose or arginine. J Clin Endocrinol Metab. 1999;84(4):1386–1390.
   PubMed Web of Science ®Google Scholar
• Haffner SM, Mykkänen L, Valdez RA, et al. Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome. J Clin Endocrinol Metab. 1994;79(6):1806–1810.
   PubMed Web of Science ®Google Scholar
• Warram JH, Sigal RJ, Martin BC, et al. Natural history of impaired glucose tolerance: follow-up at Joslin Clinic. Diabet Med. 1996;13(9 Suppl 6):S40–45.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Leonetti DL, Prigeon RL, et al. Proinsulin levels predict the development of non-insulin-dependent diabetes mellitus (NIDDM) in Japanese-American men. Diabet Med. 1996;13(9 Suppl 6):S63–66.
   PubMed Web of Science ®Google Scholar
• Hanley AJG, McKeown-Eyssen G, Harris SB, et al. Cross-sectional and prospective associations between abdominal adiposity and proinsulin concentration. J Clin Endocrinol Metab. 2002;87(1):77–83.
   PubMed Web of Science ®Google Scholar
• Vangipurapu J, Stančáková A, Kuulasmaa T, et al. Both fasting and glucose-stimulated proinsulin levels predict hyperglycemia and incident type 2 diabetes: a population-based study of 9396 Finnish men. Plos ONE. 2015;10(4):e0124028.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 1992;15(3):318–368.
   PubMed Web of Science ®Google Scholar
• Saad MF, Kahn SE, Nelson RG, et al. Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1990;70(5):1247–1253.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Leonetti DL, Prigeon RL, et al. Relationship of proinsulin and insulin with noninsulin-dependent diabetes mellitus and coronary heart disease in Japanese-American men: impact of obesity – clinical research center study. J Clin Endocrinol Metab. 1995;80(4):1399–1406.
   PubMed Web of Science ®Google Scholar
• Wang PW, Abbasi F, Carantoni M, et al. Insulin resistance does not change the ratio of proinsulin to insulin in normal volunteers. J Clin Endocrinol Metab. 1997;82(10):3221–3224.
   PubMed Web of Science ®Google Scholar
• Mykkänen L, Haffner SM, Hales CN, et al. The relation of proinsulin, insulin, and proinsulin-to-insulin ratio to insulin sensitivity and acute insulin response in normoglycemic subjects. Diabetes. 1997;46(12):1990–1995.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Beard JC, Schwartz MW, et al. Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes. 1989;38(5):562–568.
   PubMed Web of Science ®Google Scholar
• Langenfeld MR, Forst T, Standl E, et al. IRIS II study: sensitivity and specificity of intact proinsulin, adiponectin, and the proinsulin/adiponectin ratio as markers for insulin resistance. Diabetes Technol Ther. 2004;6(6):836–843.
   PubMedGoogle Scholar
• Shimizu M, Kawazu S, Tomono S, et al. Age-related alteration of pancreatic beta-cell function. Increased proinsulin and proinsulin-to-insulin molar ratio in elderly, but not in obese, subjects without glucose intolerance. Diabetes Care. 1996;19(1):8–11.
   PubMed Web of Science ®Google Scholar
• Røder ME, Porte D, Schwartz RS, et al. Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1998;83(2):604–608.
   PubMed Web of Science ®Google Scholar
• Nagi DK, Ali VM, Walji S, et al. Hyperinsulinemia in nondiabetic Asian subjects using specific assays for insulin, intact proinsulin, and des-31, 32-proinsulin. Diabetes Care. 1996;19(1):39–42.
   PubMed Web of Science ®Google Scholar
• Fritsche A, Madaus A, Stefan N, et al. Relationships among age, proinsulin conversion, and beta-cell function in nondiabetic humans. Diabetes. 2002;51(Suppl 1):S234–239.
   PubMed Web of Science ®Google Scholar
• Bryhni B, Arnesen E, Jenssen TG. Associations of age with serum insulin, proinsulin and the proinsulin-to-insulin ratio: a cross-sectional study. BMC Endocr Disord. 2010;10:21.
   PubMed Web of Science ®Google Scholar
• Porte D, Kahn SE. Hyperproinsulinemia and amyloid in NIDDM. Clues to etiology of islet beta-cell dysfunction? Diabetes. 1989;38(11):1333–1336.
   PubMed Web of Science ®Google Scholar
• Seaquist ER, Kahn SE, Clark PM, et al. Hyperproinsulinemia is associated with increased beta cell demand after hemipancreatectomy in humans. J Clin Invest. 1996;97(2):455–460.
   PubMed Web of Science ®Google Scholar
• Breuer TGK, Menge BA, Banasch M, et al. Proinsulin levels in patients with pancreatic diabetes are associated with functional changes in insulin secretion rather than pancreatic beta-cell area. Eur J Endocrinol. 2010;163(4):551–558.
   PubMed Web of Science ®Google Scholar
• Mykkänen L, Haffner SM, Kuusisto J, et al. Serum proinsulin levels are disproportionately increased in elderly prediabetic subjects. Diabetologia. 1995;38(10):1176–1182.
   PubMed Web of Science ®Google Scholar
• Røder ME, Knip M, Hartling SG, et al. Disproportionately elevated proinsulin levels precede the onset of insulin-dependent diabetes mellitus in siblings with low first phase insulin responses. The Childhood Diabetes in Finland Study Group. J Clin Endocrinol Metab. 1994;79(6):1570–1575.
   PubMed Web of Science ®Google Scholar
• Kahn SE, McCulloch DK, Schwartz MW, et al. Effect of insulin resistance and hyperglycemia on proinsulin release in a primate model of diabetes mellitus. J Clin Endocrinol Metab. 1992;74(1):192–197.
   PubMed Web of Science ®Google Scholar
• Røder ME, Kahn SE. Suppression of beta-cell secretion by somatostatin does not fully reverse the disproportionate proinsulinemia of type 2 diabetes. Diabetes. 2004;53(Suppl 3):S22–25.
   PubMed Web of Science ®Google Scholar
• Laedtke T, Kjems L, Pørksen N, et al. Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. Am J Physiol Endocrinol Metab. 2000;279(3):E520–528.
   PubMed Web of Science ®Google Scholar
• Beer SF, O’Rahilly S, Spivey RS, et al. Plasma proinsulin in first-degree relatives of type 2 diabetic subjects. Diabetes Res. 1990;14(2):51–54.
   PubMedGoogle Scholar
• Gelding SV, Andres C, Niththyananthan R, et al. Increased secretion of 32,33 split proinsulin after intravenous glucose in glucose-tolerant first-degree relatives of patients with non-insulin dependent diabetes of European, but not Asian, origin. Clin Endocrinol (Oxf). 1995;42(3):255–264.
   PubMed Web of Science ®Google Scholar
• Kirchhoff K, Machicao F, Haupt A, et al. Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion. Diabetologia. 2008;51(4):597–601.
   PubMed Web of Science ®Google Scholar
• Stolerman ES, Manning AK, McAteer JB, et al. TCF7L2 variants are associated with increased proinsulin/insulin ratios but not obesity traits in the Framingham Heart Study. Diabetologia. 2009;52(4):614–620.
   PubMed Web of Science ®Google Scholar
• Majithia AR, Jablonski KA, McAteer JB, et al. Association of the SLC30A8 missense polymorphism R325W with proinsulin levels at baseline and after lifestyle, metformin or troglitazone intervention in the diabetes prevention program. Diabetologia. 2011;54(10):2570–2574.
   PubMed Web of Science ®Google Scholar
• Heni M, Haupt A, Schäfer SA, et al. Association of obesity risk SNPs in PCSK1 with insulin sensitivity and proinsulin conversion. BMC Med Genet. 2010;11:86.
   PubMed Web of Science ®Google Scholar
• Strawbridge RJ, Dupuis J, Prokopenko I, et al. Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes. 2011;60(10):2624–2634.
   PubMed Web of Science ®Google Scholar
• Gabbay KH, DeLuca K, Fisher JN, et al. Familial hyperproinsulinemia. An autosomal dominant defect. N Engl J Med. 1976;294(17):911–915.
   PubMed Web of Science ®Google Scholar
• Chan SJ, Seino S, Gruppuso PA, et al. A mutation in the B chain coding region is associated with impaired proinsulin conversion in a family with hyperproinsulinemia. Proc Natl Acad Sci U S A. 1987;84(8):2194–2197.
   PubMed Web of Science ®Google Scholar
• Barbetti F, Raben N, Kadowaki T, et al. Two unrelated patients with familial hyperproinsulinemia due to a mutation substituting histidine for arginine at position 65 in the proinsulin molecule: identification of the mutation by direct sequencing of genomic deoxyribonucleic acid amplified by polymerase chain reaction. J Clin Endocrinol Metab. 1990;71(1):164–169.
   PubMed Web of Science ®Google Scholar
• Yano H, Kitano N, Morimoto M, et al. A novel point mutation in the human insulin gene giving rise to hyperproinsulinemia (proinsulin Kyoto). J Clin Invest. 1992;89(6):1902–1907.
   PubMed Web of Science ®Google Scholar
• Oohashi H, Ohgawara H, Nanjo K, et al. Familial hyperproinsulinemia associated with NIDDM. A case study. Diabetes Care. 1993;16(10):1340–1346.
   PubMed Web of Science ®Google Scholar
• Röder ME, Vissing H, Nauck MA. Hyperproinsulinemia in a three-generation Caucasian family due to mutant proinsulin (Arg65-His) not associated with impaired glucose tolerance: the contribution of mutant proinsulin to insulin bioactivity. J Clin Endocrinol Metab. 1996;81(4):1634–1640.
   PubMed Web of Science ®Google Scholar
• Revers RR, Henry R, Schmeiser L, et al. The effects of biosynthetic human proinsulin on carbohydrate metabolism. Diabetes. 1984;33(8):762–770.
   PubMed Web of Science ®Google Scholar
• Vestergaard H, Klein HH, Hansen T, et al. Severe insulin-resistant diabetes mellitus in patients with congenital muscle fiber type disproportion myopathy. J Clin Invest. 1995;95(4):1925–1932.
   PubMed Web of Science ®Google Scholar
• Warren-Perry MG, Manley SE, Ostrega D, et al. A novel point mutation in the insulin gene giving rise to hyperproinsulinemia. J Clin Endocrinol Metab. 1997;82(5):1629–1631.
   PubMed Web of Science ®Google Scholar
• Matheus AS De M, Tannus LRM, Cobas RA, et al. Impact of diabetes on cardiovascular disease: an update. Int J Hypertens. 2013;2013:653789.
   PubMedGoogle Scholar
• Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe. Lancet. 1999;354(9179):617–621.
   PubMed Web of Science ®Google Scholar
• Pyörälä K, Savolainen E, Kaukola S, et al. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9 1/2-year follow-up of the Helsinki Policemen Study population. Acta Med Scand Suppl. 1985;701:38–52.
   PubMedGoogle Scholar
• DeFronzo RA. Insulin resistance, hyperinsulinemia, and coronary artery disease: a complex metabolic web. J Cardiovasc Pharmacol. 1992;20(Suppl 11):S1–16.
   PubMed Web of Science ®Google Scholar
• Scherrer U, Randin D, Vollenweider P, et al. Nitric oxide release accounts for insulin’s vascular effects in humans. J Clin Invest. 1994;94(6):2511–2515.
   PubMed Web of Science ®Google Scholar
• Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. Jama. 2000;283(2):221–228.
   PubMed Web of Science ®Google Scholar
• Galloway JA, Hooper SA, Spradlin CT, et al. Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience. Diabetes Care. 1992;15(5):666–692.
   PubMed Web of Science ®Google Scholar
• Nagi DK, Hendra TJ, Ryle AJ, et al. The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia. 1990;33(9):532–537.
   PubMed Web of Science ®Google Scholar
• Mohamed-Ali V, Gould MM, Gillies S, et al. Association of proinsulin-like molecules with lipids and fibrinogen in non-diabetic subjects–evidence against a modulating role for insulin. Diabetologia. 1995;38(9):1110–1116.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Leonetti DL, Prigeon RL, et al. Proinsulin as a marker for the development of NIDDM in Japanese-American men. Diabetes. 1995;44(2):173–179.
   PubMed Web of Science ®Google Scholar
• Schneider DJ, Nordt TK, Sobel BE. Stimulation by proinsulin of expression of plasminogen activator inhibitor type-I in endothelial cells. Diabetes. 1992;41(7):890–895.
   PubMed Web of Science ®Google Scholar
• Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease. Circulation. 1994;89(1):321–330.
   PubMed Web of Science ®Google Scholar
• Nordt TK, Sawa H, Fujii S, et al. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation. 1995;91(3):764–770.
   PubMed Web of Science ®Google Scholar
• Eliasson M, Røder ME, Dinesen B, et al. Proinsulin, intact insulin, and fibrinolytic variables and fibrinogen in healthy subjects. A population study. Diabetes Care. 1997;20(8):1252–1255.
   PubMed Web of Science ®Google Scholar
• Lundblad D, Dinesen B, Rautio A, et al. Low level of tissue plasminogen activator activity in non-diabetic patients with a first myocardial infarction. J Intern Med. 2005;258(1):13–20.
   PubMed Web of Science ®Google Scholar
• Zethelius B, Byberg L, Hales CN, et al. Proinsulin is an independent predictor of coronary heart disease: report from a 27-year follow-up study. Circulation. 2002;105(18):2153–2158.
   PubMed Web of Science ®Google Scholar
• Alssema M, Dekker JM, Nijpels G, et al. Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: an 11-year follow-up of the Hoorn study. Diabetes Care. 2005;28(4):860–865.
   PubMed Web of Science ®Google Scholar
• Farhan S, Jarai R, Tentzeris I, et al. Admission proinsulin is associated with mortality in patients with admission hyperglycemia during acute coronary syndrome: results from a pilot observational study. Clin Chem. 2011;57(10):1456–1460.
   PubMed Web of Science ®Google Scholar
• Kronborg J, Johnsen SH, Njølstad I, et al. Proinsulin: insulin and insulin: glucoseratios as predictors of carotid plaque growth: a population-based 7 year follow-up of the Tromsø study. Diabetologia. 2007;50(8):1607–1614.
   PubMed Web of Science ®Google Scholar
• Inoguchi T, Umeda F, Kakimoto M, et al. Chronic sulfonylurea treatment and hyperglycemia aggravate disproportionately elevated plasma proinsulin levels in patients with type 2 diabetes. Endocr J. 2000;47(6):763–770.
   PubMed Web of Science ®Google Scholar
• Pscherer S, Larbig M, Von Stritsky B, et al. In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment. J Diabetes Sci Technol. 2012;6(3):634–640.
   PubMedGoogle Scholar
• Ohkura T, Inoue K, Fujioka Y, et al. The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: a small-scale clinical study. BMC Res Notes. 2013;6:453.
   PubMedGoogle Scholar
• Pfützner A, Forst T. Elevated intact proinsulin levels are indicative of beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone. J Diabetes Sci Technol. 2011;5(3):784–793.
   PubMedGoogle Scholar